Investors
We announced our quarter 1 2024 results on Wednesday, May 1st.
Press releases
- GSK invests up to $800 million in Pennsylvania site, largest manufacturing investment in U.S.
- New data for AREXVY, GSK’s respiratory syncytial virus vaccine, show potential to help protect a broader group of adults at increased risk for RSV disease
- ViiV Healthcare shows more than 99% effectiveness in real-world studies for Apretude (cabotegravir long-acting), the only approved long-acting HIV PrEP, in data presented at IDWeek 2024
Choose your path
By bringing outstanding people together in an inclusive environment to do work that matters, we can impact the world’s health.
GSK Global links
Visit our Global site for additional features